CO6721014A2 - Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b - Google Patents
Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2bInfo
- Publication number
- CO6721014A2 CO6721014A2 CO13142398A CO13142398A CO6721014A2 CO 6721014 A2 CO6721014 A2 CO 6721014A2 CO 13142398 A CO13142398 A CO 13142398A CO 13142398 A CO13142398 A CO 13142398A CO 6721014 A2 CO6721014 A2 CO 6721014A2
- Authority
- CO
- Colombia
- Prior art keywords
- monoclonal antibody
- determining region
- humanized monoclonal
- complementarity determining
- peptide derived
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 230000000259 anti-tumor effect Effects 0.000 title abstract 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/10—Bryophyta (mosses)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42285610P | 2010-12-14 | 2010-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6721014A2 true CO6721014A2 (es) | 2013-07-31 |
Family
ID=46245158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13142398A CO6721014A2 (es) | 2010-12-14 | 2013-06-14 | Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9193797B2 (OSRAM) |
| EP (1) | EP2654769B1 (OSRAM) |
| JP (1) | JP6087289B2 (OSRAM) |
| BR (1) | BR112013015001B1 (OSRAM) |
| CO (1) | CO6721014A2 (OSRAM) |
| ES (1) | ES2804476T3 (OSRAM) |
| PT (1) | PT2654769T (OSRAM) |
| WO (1) | WO2012080822A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016013258A2 (pt) * | 2013-12-16 | 2018-01-16 | Genentech Inc | composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit |
| CN105491524B (zh) * | 2015-12-11 | 2019-04-26 | 小米科技有限责任公司 | 一种确定目标便携设备位置的方法和装置 |
| BR112019026332A2 (pt) * | 2017-07-01 | 2020-07-21 | Recepta Biopharma S A | métodos e peptídeos imunomodulatórios para modular o sistema imunológico em um indivíduo |
| IL273252B2 (en) * | 2017-09-20 | 2024-03-01 | Mersana Therapeutics Inc | Compositions and methods for predicting response to napi2b-targeted therapy |
| CA3188501A1 (en) | 2020-08-07 | 2022-02-10 | Todd Golub | Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex |
| KR102822203B1 (ko) | 2020-12-29 | 2025-06-18 | 삼성전자주식회사 | 전력 공급 장치를 이용하여 오디오 출력 장치를 찾는 방법 및 그 전력 공급 장치 |
| CN116514926B (zh) * | 2023-06-25 | 2023-08-29 | 烟台药物研究所 | 一种抗肿瘤阳离子两亲肽及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9108652D0 (en) * | 1991-04-23 | 1991-06-12 | Antisoma Ltd | Immunoreactive compounds |
| US5827498A (en) * | 1994-06-07 | 1998-10-27 | Nihon Medi-Physics Co., Ltd. | Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide |
| US6689753B1 (en) | 1999-11-05 | 2004-02-10 | Axonyx, Inc. | β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide |
| JP2007534631A (ja) * | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| WO2009097128A1 (en) | 2008-01-29 | 2009-08-06 | Ludwig Institute For Cancer Research Ltd. | Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
-
2011
- 2011-12-14 ES ES11849571T patent/ES2804476T3/es active Active
- 2011-12-14 US US13/991,688 patent/US9193797B2/en active Active
- 2011-12-14 PT PT118495712T patent/PT2654769T/pt unknown
- 2011-12-14 JP JP2013543901A patent/JP6087289B2/ja active Active
- 2011-12-14 EP EP11849571.2A patent/EP2654769B1/en active Active
- 2011-12-14 BR BR112013015001-7A patent/BR112013015001B1/pt active IP Right Grant
- 2011-12-14 WO PCT/IB2011/003053 patent/WO2012080822A2/en not_active Ceased
-
2013
- 2013-06-14 CO CO13142398A patent/CO6721014A2/es unknown
-
2015
- 2015-10-27 US US14/924,003 patent/US9896512B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012080822A9 (en) | 2016-08-11 |
| BR112013015001A2 (pt) | 2017-12-19 |
| WO2012080822A2 (en) | 2012-06-21 |
| JP2014510699A (ja) | 2014-05-01 |
| PT2654769T (pt) | 2020-07-16 |
| US9896512B2 (en) | 2018-02-20 |
| EP2654769A4 (en) | 2017-10-25 |
| BR112013015001A8 (pt) | 2018-04-17 |
| US20130315902A1 (en) | 2013-11-28 |
| US9193797B2 (en) | 2015-11-24 |
| US20160108132A1 (en) | 2016-04-21 |
| JP6087289B2 (ja) | 2017-03-01 |
| BR112013015001B1 (pt) | 2021-10-13 |
| EP2654769B1 (en) | 2020-04-15 |
| ES2804476T3 (es) | 2021-02-08 |
| EP2654769A2 (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6721014A2 (es) | Péptido antitumoral derivado de una región determinante de complementariedad de un anticuerpo monoclonal humanizado al transportador napi2b | |
| CY1123865T1 (el) | Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| DOP2021000023A (es) | Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr | |
| UY36404A (es) | ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN | |
| EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| EA201391509A1 (ru) | Твердофазные формы кабазитаксела и способы их получения | |
| MX2016014189A (es) | Anticuerpos anti ligando 1 de muerte programada (b7-h1) y anti antigeno 4 de linfocito t citotoxico (anti-ctla-4) para tratar el cancer de pulmon no microcitico. | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| NI201500024A (es) | Anticuerpos y vacunas para utilizarse en el tratamiento de cánceres por ror1 y para inhibir la metástasis. | |
| CR20180519A (es) | Neoantígenos y métodos de su uso | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| MX2016002826A (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| MX2017000205A (es) | Anticuerpos anti-tau humanizados. | |
| CO2017001023A2 (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| EA201592269A1 (ru) | Способы и композиции для снижения иммуносупрессии опухолевыми клетками | |
| EA201490039A1 (ru) | Химерные и гибридные полипептиды фактора viii и способы их применения | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| BR112012021327B8 (pt) | anticorpo monoclonal anti-her2 humanizado, método de preparação e uso do mesmo. | |
| BR112012011528A2 (pt) | métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso |